9 results on '"Shanta, V"'
Search Results
2. Curbing tobacco's toll starts with the professionals: World No Tobacco Day
- Author
-
Boyle, Peter, Ariyaratne, M.A.Y., Bartelink, Harry, Baselga, Jose, Berns, Anton, Brawley, Otis W., Burns, Harry, Davidov, Michail, Dinshaw, K.A., Dresler, Carolyn, Eggermont, Alexander M.M., Gajurel, Damodar, Gordina, Galina, Gray, Nigel, Kakizoe, Tadao, Karki, Balman Singh, Kasler, Miklos, Kerr, David J., Khayat, David, Kiselev, Alexander, Khuhaprema, Thiravud, Klocker, Helmut, Levshin, Valdimir, Martin-Moreno, Jose M., McVie, J. Gordon, Mendelsohn, John, Napalkov, Nikolai P., Ngoma, Twalib A., Park, Jae-Gahb, Philip, Theirry, Potschke-Langer, Martina, Poudal, Hom Nath, Rajan, B., Ringborg, Ulrik, Rodger, Alan, Seffrin, John R., Shanta, V., Shrestha, Murari Man, Thomas, Robert, Tursz, Thomas, de Valeriola, Dominique, Veronesi, Umberto, Wiestler, Otmar D., Zaridze, David, Zatonski, Witold, and Zeng, Yi-Xin
- Subjects
World Health Organization -- Services ,Cancer -- Risk factors ,Smoking -- Risk factors ,Smoking -- Control - Published
- 2005
3. Retrospective analysis of locally advanced noninflammatory breast cancer from Chennai, South India, 1990-1999.
- Author
-
Shanta V, Swaminathan R, Rama R, and Radhika R
- Abstract
Purpose: This was a retrospective observational study to elicit the outcome of the therapeutic strategy of concurrent neoadjuvant chemoradiotherapy protocol for locally advanced breast cancer. Methods and Materials: A large series of 1,117 consecutive cases of locally advanced breast cancer treated at the Cancer Institute (WIA), in Chennai, South India, between 1990 and 1999 and followed through 2004 formed the basis for this study. Disease-free survival was the main outcome, and nodal and tumor downstaging were the intermediate outcome measures studied. Results: Primary tumor downstaging was observed in 45% and nodal downstaging in 57.5%. The disease-free survival rate of nodal downstaged patients at 5, 10, and 15 years was 75%, 65%, and 58%, respectively. The corresponding rates for pre- and postoperative node-negative patients were 70%, 60%, and 59%. The best survival was seen among those who were tumor and node negative postoperatively. Nodal downstaging halved the risk of disease recurrence and death compared with node positivity, irrespective of tumor sterility. Conclusions: A randomized trial using cyclophosphamide, methotrexate, and 5-fluorouracil vs. an anthracycline-based regimen in the setting of concurrent chemoradiotherapy appears indicated. Additional preoperative chemotherapy to maximize nodal and tumor downstaging should be investigated. A change in postoperative chemotherapy according to nodal status could also be explored. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
4. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year peroid
- Author
-
Magrath, I., Shanta, V., Advani, S., Adde, M., Arya, L.S., Banavali, S., Bhargava, M., Bhatia, K., Gutiérrez, M., Liewehr, D., Pai, S., Sagar, T.G., and Venzon, D.
- Subjects
- *
LYMPHOBLASTIC leukemia , *LYMPHOCYTIC leukemia , *BLOOD testing , *CANCER treatment - Abstract
Abstract: In the 1970s, survival rates after treatment for acute lymphoblastic leukaemia (ALL) in children and young adults (less than 25 years) in India were poor, even in specialised cancer centres. The introduction of a standard treatment protocol (MCP841) and improvements in supportive care in three major cancer centres in India led to an increase in the event-free survival rate (EFS) from less than 20% to 45–60% at 4 years. Results of treatment with protocol MCP841 between 1984 and 1990 have been published and are briefly reviewed here. In addition, previously unpublished data from 1048 patients treated between 1990 and 1997 are reported. Significant differences in both patient populations and treatment outcome were noted among the centres. In one centre, a sufficiently large number of patients were treated each year to perform an analysis of patient characteristics and outcome over time. Although steady improvement in outcome was observed, differences in the patient populations in the time periods examined were also noted. Remarkably, prognostic factors common to all three centres could not be defined. Total white blood cell count (WBC) was the only statistically significant risk factor identified in multivariate analyses in two of the centres. Age is strongly associated with outcome in Western series, but was not a risk factor for EFS in any of the centres. Comparison of patient characteristics with published series from Western nations indicated that patients from all three Indian centres had more extensive disease at presentation, as measured by WBC, lymphadenopathy and organomegaly. The proportions of ALLs with precursor T-cell immunophenotypes, particularly in Chennai, were also increased, even when differences in the age distribution were taken into consideration (in <18-year olds, the range was 21.1–42.7%), and in molecular analyses performed on leukaemic cells from over 250 patients less than 21-years-old with precursor B-cell ALL, a lower frequency of TEL-AML1-positive ALL cases than reported in Western series was observed. The worse outcome of treatment in Indian patients compared with recent Western series was probably due to the higher rate of toxic deaths in the Indian patients, and possibly also due to their more extensive disease – which is, at least partly, a consequence of delay in diagnosis. Differences in the spectrum of molecular subtypes may also have played a role. The higher toxic death rates observed are likely to have arisen from a combination of more extensive disease at diagnosis, co-morbidities (e.g., intercurrent infections), differences in the level of hygiene achievable in the average home, poor access to acute care, and more limited supportive care facilities in Indian hospitals. Toxic death was not associated with WBC at presentation, and hence would tend to obscure the importance of this, and, potentially, other risk factors, as prognostic indicators. Since the prevalence of individual risk factors varies in different populations and over time, their relative importance would also be expected to vary in different centres and in different time periods. This was, in fact, observed. These findings have important implications for the treatment of ALL in countries of low socioeconomic status; it cannot be assumed that risk factors defined in Western populations are equally appropriate for patient assignment to risk-adapted therapy groups in less affluent countries. They also demonstrate that heterogeneity in patient populations and resources can result in significant differences in outcome, even when the same treatment protocol is used. This is often overlooked when comparing published patient series. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
5. Corrigendum to “Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year peroid” [Eur J Cancer 41 (2005) 1570–1583]
- Author
-
Magrath, I., Shanta, V., Advani, S., Adde, M., Arya, L.S., Banavali, S., Bhargava, M., Bhatia, K., Gutiérrez, M., Liewehr, D., Pai, S., Sagar, T.G., and Venzon, D.
- Published
- 2007
- Full Text
- View/download PDF
6. PCR–heteroduplex analysis of TCR γ, δ and TAL-1 deletions in T-acute lymphoblastic leukemias: implications in the detection of minimal residual disease
- Author
-
Nirmala, K., Rajalekshmy, K.R., Raman, S.G., Shanta, V., and Rajkumar, T.
- Subjects
- *
LYMPHOBLASTIC leukemia , *POLYMERASE chain reaction , *T cell receptors - Abstract
Detection of MRD remains one of the major goals in the treatment of acute lymphoblastic leukemia (ALL). We have used the polymerase chain reaction (PCR)–heteroduplex (HD) analysis to assess and confirm the clonal expansion of T cell receptor (TCR) γ and δ gene rearrangements in 24 T-ALL patients at diagnosis. 52.4% revealed Vδ1-Jδ1; 48% Vδ2-Dδ3; 62.5% Vγ1-Jγ1 and 46% both Vδ1-Jδ1 and Vγ1-Jγ1 clonal rearrangements. 6/24 patients had TAL-1 deletion. These clonal markers were used to monitor MRD in remission/relapse bone marrow samples for periods ranging from 6 to 75 months after diagnosis. Patients who relapsed and died revealed a continuous PCR–HD positivity in their clinical remission bone marrow samples. HD analysis established identical diagnostic clone at relapse. Patients who are in long-term clinical and morphological remission achieved PCR–HD negativity in their 8–12 months bone marrow remission samples and continue to be PCR–HD negative. MRD monitored in six patients with two diagnostic PCR–HD positive clonal markers reveal an identical pattern ensuring circumvention of false positive and negative results. Thus, we conclude that PCR followed by HD analysis is a useful technique to monitor MRD in remission/relapse samples in ALL patients. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
7. Delivery of affordable and equitable cancer care in India.
- Author
-
Pramesh, C S, Badwe, Rajendra A, Borthakur, Bibhuti B, Chandra, Madhu, Raj, Elluswami Hemanth, Kannan, T, Kalwar, Ashok, Kapoor, Sanjay, Malhotra, Hemant, Nayak, Sukdev, Rath, Goura K, Sagar, T G, Sebastian, Paul, Sarin, Rajiv, Shanta, V, Sharma, Suresh C, Shukla, Shilin, Vijayakumar, Manavalan, Vijaykumar, D K, and Aggarwal, Ajay
- Subjects
- *
CANCER patient care , *MEDICAL care , *PUBLIC health , *PUBLIC spending , *MEDICAL care costs , *CANCER diagnosis , *MEDICAL economics - Abstract
Summary: The delivery of affordable and equitable cancer care is one of India's greatest public health challenges. Public expenditure on cancer in India remains below US$10 per person (compared with more than US$100 per person in high-income countries), and overall public expenditure on health care is still only slightly above 1% of gross domestic product. Out-of-pocket payments, which account for more than three-quarters of cancer expenditures in India, are one of the greatest threats to patients and families, and a cancer diagnosis is increasingly responsible for catastrophic expenditures that negatively affect not only the patient but also the welfare and education of several generations of their family. We explore the complex nature of cancer care systems across India, from state to government levels, and address the crucial issues of infrastructure, manpower shortages, and the pressing need to develop cross-state solutions to prevention and early detection of cancer, in addition to governance of the largely unregulated private sector and the cost of new technologies and drugs. We discuss the role of public insurance schemes, the need to develop new political mandates and authority to set priorities, the necessity to greatly improve the quality of care, and the drive to understand and deliver cost-effective cancer care programmes. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
8. Cancer research in India: national priorities, global results.
- Author
-
Sullivan, Richard, Badwe, Rajendra A, Rath, Goura K, Pramesh, C S, Shanta, V, Digumarti, Raghunadharao, D'Cruz, Anil, Sharma, Suresh C, Viswanath, Lokesh, Shet, Arun, Vijayakumar, Manavalan, Lewison, Grant, Chandy, Mammen, Kulkarni, Priyadarshini, Bardia, M R, Kumar, Shaleen, Sarin, Rajiv, Sebastian, Paul, Dhillon, Preet K, and Rajaraman, Preetha
- Subjects
- *
CANCER research , *GOVERNMENT policy , *SCIENTISTS , *FUND accounting , *PUBLIC health - Abstract
Summary: Over the past 20 years, cancer research in India has grown in size and impact. Clinicians, scientists, and government and state policy makers in India have championed cancer research, from studies to achieve low-tech, large-scale health outcomes to some of the most advanced areas of fundamental cancer science. In this paper, we frame public policy discussions about cancer with use of an in-depth analysis of research publications from India. Cancer research in India is a complex environment that needs to balance public policy across many competing agendas. We identify major needs across these environments such as those for increased research capacity and training and protected time for clinical researchers; for more support from states and enhanced collaborative funding programmes from government; for development of national infrastructures across a range of domains (ie, clinical trials, tissue banking, registries, etc); and for a streamlined and rational regulatory environment. We also discuss improvements that should be made to translate research into improvements in cancer outcomes and public health. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. The growing burden of cancer in India: epidemiology and social context.
- Author
-
Mallath, Mohandas K, Taylor, David G, Badwe, Rajendra A, Rath, Goura K, Shanta, V, Pramesh, C S, Digumarti, Raghunadharao, Sebastian, Paul, Borthakur, Bibhuti B, Kalwar, Ashok, Kapoor, Sanjay, Kumar, Shaleen, Gill, Jennifer L, Kuriakose, Moni A, Malhotra, Hemant, Sharma, Suresh C, Shukla, Shilin, Viswanath, Lokesh, Chacko, Raju T, and Pautu, Jeremy L
- Subjects
- *
CANCER research , *EPIDEMIOLOGY , *DISEASE incidence , *SOCIAL problems , *DEMOGRAPHIC surveys - Abstract
Summary: Cancer can have profound social and economic consequences for people in India, often leading to family impoverishment and societal inequity. Reported age-adjusted incidence rates for cancer are still quite low in the demographically young country. Slightly more than 1 million new cases of cancer are diagnosed every year in a population of 1·2 billion. In age-adjusted terms this represents a combined male and female incidence of about a quarter of that recorded in western Europe. However, an estimated 600 000–700 000 deaths in India were caused by cancer in 2012. In age-standardised terms this figure is close to the mortality burden seen in high-income countries. Such figures are partly indicative of low rates of early-stage detection and poor treatment outcomes. Many cancer cases in India are associated with tobacco use, infections, and other avoidable causes. Social factors, especially inequalities, are major determinants of India's cancer burden, with poorer people more likely to die from cancer before the age of 70 years than those who are more affluent. In this first of three papers, we examine the complex epidemiology of cancer, the future burden, and the dominant sociopolitical themes relating to cancer in India. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.